The use of cannabis as a medical tool for patients in Canada has expanded greatly thanks to the advancements of the policy implemented by the federal government as it seeks full legalization of the drug. More and more patients are looking into the potential of cannabis as a legitimate tool for combating several diseases.
With a clearer path towards medical use, data and tests are crucial for the development of cannabis in this industry–an area where the market has been severely lacking. A software company in Toronto is trying to change the shortage of data available to the whole industry.
Strainprint was founded in 2016 by five medical cannabis user under the Canadian Access to Cannabis for Medical Purposes Regulations (ACMPR) program who found the lack of data affected what type of medication exactly they wanted and the effects they could have on their treatment. Now, the company manages a large scale set of data updated on a daily basis by enthusiastic users who want to share their experience.
The Investing News Network (INN) had the opportunity to discuss this project with Dave Berg, Strainprint’s chief technology officer. During the interview, we discuss the potential this data has for patients looking for answers, the use of this data he’s seen and how this information could affect licensed producers (LPs) and medical researchers alike. Berg also expands on the molecular level type of research needed to fully evaluate cannabis, what really matters when comparing different strains and why that alone is so difficult.
Strainprint announced the launch of a new ambassador program across North America, encouraging researchers to take a closer look at their data tools in their paths of medical cannabis studies, with support from the company.
With that in mind, the interview has been edited for clarity and brevity. Read on below to find out what Berg had to say.
Investing News Network: Tell me about the idea of Strainprint?
Dave Berg: It came out of frustration with the lack of data that’s available to medicinal cannabis patients when they are on-boarding into the program. Specifically, in this case, we’re talking about the (ACMPR) program.
As patients, if you’re new to cannabis there’s a lot of supply side data in terms of how efficient growers are, how much fertilizer has been used, the relative cost. But when it comes to prescribing guidelines–or understanding the nuances between a specific strain and its effects on a person– it’s all pretty alien, at least for the vast majority of the population.
We [each] started to do some digging for our personal purposes and we were quite shocked that there was no real solution out there that was gathering that data; so we decided that we would build it. We decided to look at it from a patient’s perspective first, [and] from there it went to the other applications for the data within the larger industry.
There’s no really strong observational data set that allows us to make proper decisions.
INN: About the general lack of data, it seems that’s something that’s been slowing down the development of more sophisticated cannabis therapies. Researchers simply don’t have a lot of data to evaluate. Do you think the lack of research is mostly due to the illegal nature of the drug?
DB: That’s in part in terms of the reason why there may not be more clinical or observational studies because it’s a scheduled drug. That’s certainly changing in Canada and the US over time. What became apparent to me is when you’re looking at cannabis as a product–in Canada as an example–there are 1,200 legally grown strains for sale through LPs. So as a medical patient I can go in and get any of those strains. If I order them, if I know what I’m ordering but there were really no guidelines when I got my prescription to purchase. My doctor could tell me if I wanted something that is a non-psychoactive and good for inflammation to try CBD, and if I want to have a good night sleep to try sativa.
What we found is, it’s less about the category of the strain and more about the underlying chemical composition of that strain and that strain itself can vary in composition not only from grower to grower but also in between from batch to batch. Taking an approach that’s more of a molecular approach, which is what doctors and most of us are used to, is increasingly difficult because the compound of cannabis is always changing based on batch to batch.
For that reason, it’s been very difficult for people to study cannabis in a clinical way, but there’s been a ton observational data clearly that people have said ‘you know this is great for my arthritis, this is great for my tendonitis, this helped me through my cancer treatments or others. There’s no really strong observational data set that allows us to make proper decisions.
INN: You guys announced this ambassador research program and the idea is that researchers are using your tools but who are these researchers specifically?
DB: Strainprint as a tool is free to patients across North America and is also free for users to share your data with physicians. So if you’re taking a treatment plan and you want to log your use and share your efficacy, you can show that to your doctor. The doctors that are currently running in-clinic typically gather their data through a personal interview… but they are not gathering real time data.
What Strainprint allows patients to do is chronicle their cannabis use and measure the efficacy based on the way they decide to take cannabis that can be dosing, that’s strain type as well as ingestion method. That builds quite a large data set that we provide back to the patient so that they can make informed decisions about what is working for them and what is not.
What we quickly realized is the data that we’re gathering there that helps individuals en mass, also when it’s anonymized … is a very valuable tool for study. We have the ability to customize the Strainprint product using activation code and what that does it creates a sandbox of data and a customized version of Strainprint. That allows us to specify what type of strains are being studied. We can specify specific type of ingestion methods and also customize the look and feel. That allows people to gather data on a specific subset of users while they still also contribute their anonymous data to the global data.
The ambassador program is about making people aware that we are providing this tool that will help them to guide their cannabis research. We track over 300 medical conditions and symptoms on the tool, we’re approaching 2,000 different strains on our database which is updated on a regular basis. We want to work with leading researchers to help them advance cannabis research so we announced Dr. Michelle Ross she’s with the IMPACT Network and she is our first ambassador.
“It’s not just about identifying the efficacy of a given strain, it’s about understanding what are the chemical constituents”
INN: Have you seen any other rising interested parties or the larger impact from the work that you guys are doing so far?
DB: It certainly exceeded all of our expectations. Strainprint started off as a hobby for the five of us. Based on the general interest of the public in the way this tool is actually helping people, we’ve seen a dramatic uptake in its use. We’ve been out for just over 20 weeks and we’re about to surpass one million independent data records. It’s a lot of data that’s being collected and is making a real difference. We’re seeing commercial producers using this data, LPs [use it] to better understand the need of their patients or their customers. Clinics are also looking at this data to better guide patient care and understand the way people are using cannabis to better their results and then finally researchers are looking at a way to develop the next generation of therapeutics.
It’s not just about identifying the efficacy of a given strain, it’s about understanding what are the chemical constituents, you got the cannabinoids and then you got the terpenes as well. we’re breaking it down into the chemical composition so that when we identify a homogenous group of users in the data set that are getting a systematic release, we can actually look at the chemical composition, which helps guide therapeutic product design and new delivery mechanisms and obviously new compounded products.
INN: Ideally with all these data inputs and records, in the purpose of it is to help patients become more informed of the cannabis products available to them?
DB: It starts with the patient. It always has, that’s where the company came from. We’re all patients and we want to provide value back to help patients navigate and make the right decisions to improve their quality of life. The other side of it is we wanted to make sure there was a tool that enabled these patients to have an open dialogue with their physicians while enabling them to talk in a language that their physicians are used to conversing with. Making it more of a clinical type of discussion by providing the data that they require.
INN: Besides the impact of the network through the ambassadors you mentioned are there any other plans for partnerships you guys are thinking about.
DB: Over the next two months we will be announcing another six large scale research studies. These are going to be in the areas of anxiety disorders, post-traumatic stress, Alzheimer’s, oncology as well as inflammatory diseases and autoimmune diseases. This is the beginning of a number of studies.
INN: Thank you for your time today Dave.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in contributed article. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
Ayurcann Holdings Corp. (CSE: AYUR) (the “Company” or “Ayurcann”) an integrated Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, announces the granting of stock options and restricted share units.
The Company has announced that it has granted incentive stock options to directors, officers, employees and consultants of the Company to purchase an aggregate of 1,000,100 common shares under the Company’s Stock Option Plan. Each option is exercisable at a price of $0.16 per common share, expires three years from the date of grant and vest six months from the date of the grant.
The Company has also granted restricted share unit grants, pursuant to the Company’s Restricted Share Unit plan, dated April 1, 2021, totaling 1,548,875 to certain eligible participants.
For further information, please contact:
Igal Sudman, Chairman, Chief Executive Officer and Corporate Secretary
Ayurcann Holdings Corp.
About Ayurcann Holdings Corp.:
Ayurcann is a leading post-harvest solution provider with a focus on providing and creating custom processes and pharma grade products for the adult use and medical cannabis industry in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing best-in-class, proprietary services including ethanol extraction, formulation, product development and custom manufacturing.
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
News Provided by GlobeNewswire via QuoteMedia
A planned business merger between two leading cannabis producers hit a small delay this week as a critical vote got moved.
Keep reading to find out more cannabis highlights from the past five days.
Tilray delays critical shareholder meeting
On Thursday (April 15), Tilray (NASDAQ:TLRY) announced it will be postponing its shareholder vote on the fate of its merger with Aphria (NASDAQ:APHA,TSX:APHA). It will take place on April 30 instead of April 16.
Neither cannabis company offered an explanation for the change. Tilray has asked shareholders to participate in this vote regardless of how many shares they may hold. “Tilray stockholders who have not already voted, or wish to change their vote, are strongly encouraged to do so,” the company said.
This news came days after Aphria shareholders overwhelmingly voted in favor of the business transaction, with a total of 99.38 percent of shareholders voting for the deal to continue. Confirmation from Aphria Chairman and CEO Irwin Simon indicated the partnership was en route to being complete.
This past week Aphria also released financial results for the third quarter of its 2021 fiscal year, in which the firm highlights the overall direction of the company with the Tilray deal.
“We expect to have a tremendous runway for long-term sustainable growth as we build upon our existing foundation in Canada and internationally by increasing the scale of our global operations,” Simon said in a statement.
Cannabis retailer celebrates digital trend
Bidding for the piece, named “Non-Fungible Toke“ started at a price of C$4.20. The retailer plans to donate the proceeds to two charities, Second Harvest and Less.
The latter is designed to counter the carbon footprint of blockchain technology, a common criticism drawn against the rise of NFTs and other novel technologies.
As of 11:00 a.m. EST on Friday (April 16), the NFT bid was up to C$169.11.
Cannabis company news
- The Valens Company (TSX:VLNS,OTCQX:VLNCF) issued its financial report for the first quarter of its 2021 fiscal year. In its results, the company highlights a net revenue uptick of 24.7 percent from the previous quarter, resulting in C$20 million for the period.
- Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) closed a public offering of 5 million subordinate voting shares at a price of C$50 each for total gross proceeds of C$287.5 million. The company celebrated its financial position after an offering in January, which will lead to the pursuit of merger and acquisition targets.
- Australis Capital (CSE:AUSA,OTCQB:AUSAF) appointed Jason Dyck as its new chief science officer and chairman of the firm’s scientific advisory board. Dyck previously served as an executive at Aurora Cannabis (NASDAQ:ACB,TSX:ACB), leading the scientific efforts for the cannabis producer. “I look forward to providing AUSA with advice and direction in its scientific efforts towards bringing innovations to market with immediate and significant commercial appeal,” Dyck said.
- Truss Beverage, a cannabis drinks venture co-owned by Molson Coors Beverage Company (NYSE:TAP,TSX:TPX) and HEXO (NYSE:HEXO,TSX:HEXO), released the details of its new lineup of infused beverages. Six new drinks will become available around the summer and are intended to pair with the season.
Don’t forget to follow us @INN_Cannabis for real-time updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Partnerships with Minardi Law , Minorities for Medical Marijuana, CultivatED, and the Georgia Justice Project will include clinics and virtual events across Florida , Georgia , and Massachusetts
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today a series of expungment clinics located throughout south and central Florida as well as virtual events in Georgia and Massachusetts . The clinics are part of the Company’s celebration of the 50 th anniversary of 420.
During the month of April, Minardi Law has hosted expungment clinics and will be hosting two more as follows:
- Releaf Patient Appreciation Day, April 17 th ( Valrico )
- First Annual 4/20 Event ( St. Petersburg Beach )
At these clinics, an attorney will be present to review records and see if someone is eligible for a sealing or expungment of their records. As part of the events, Trulieve will be helping cover the costs for finger prints, legal fees, and court costs.
Trulieve is working with Minorities for Medical Marijuana (“M4MM”) to host a 4/20 Expungement Clinic, part of M4MM’s Project Clean Slate. This event will take place on Saturday, April 24, 2021 , from 9:30am – 4:30pm at Riviera Beach City Hall. Anyone seeking to take place in this event is required to register in advance at http://trulieve.cc/expungementpreregistration .
In addition, Trulieve is sponsoring the First Friday Series , a weekly virtual event from the Georgia Justice Project to help Georgia citizens with record restrictions, and is also sponsoring the Fellowship Presentation and Expungement Clinic being offered through CultivateEd and GBLS on Friday, April 23 from 3:00pm – 4:00pm . You can register for the Massachusetts expungement clinic in advance here: HTTPS://BIT.LY/2Q655KK
“Our mission as a company has always been to improve people’s lives,” said Trulieve CEO Kim Rivers . “We’ve always been dedicated to improving the communities we call home. Partnering with Minardi Law , Minorities for Medical Marijuana, Georgia Justice Project and CultivatED on these clinics was a simple decision for us; we encourage anyone seeking help with the expungement process to attend one of these clinics in your own state to start the process.”
For more information about Trulieve and the April expungment clinics, please visit www.Trulieve.com .
Trulieve is primarily a vertically integrated “seed-to-sale” company in the U.S. and is the first and largest fully licensed medical cannabis company in the State of Florida . Trulieve cultivates and produces all of its products in-house and distributes those products to Trulieve-branded stores (dispensaries) throughout the State of Florida , as well as directly to patients via home delivery. Trulieve also has operations in California , Massachusetts , Connecticut and Pennsylvania. Trulieve is listed on the Canadian Securities Exchange under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF.
To learn more about Trulieve, visit www.Trulieve.com .
SOURCE Trulieve Cannabis Corp.
News Provided by PR Newswire via QuoteMedia
Seth Rogen’s New Cannabis Brand are Now Available at Apothecarium Dispensaries in San Francisco , Berkeley and Capitola
The Apothecarium is offering cannabis from Houseplant, the cannabis lifestyle brand founded by Seth Rogen and Evan Goldberg at its five California dispensaries. The Apothecarium has three San Francisco locations (Castro, SOMA and Marina ) and one each in Berkeley and Capitola (outside of Santa Cruz ).
“With the vast number of dispensaries in California , we put a lot of effort into identifying the right ones that align with Houseplant’s values,” said Seth Rogen , Co-Founder of Houseplant. “The Apothecarium shares the same commitment to creating a strong consumer experience that we pride ourselves on and we are thrilled to bring our three initial strains to their stores in the Bay Area.”
Houseplant is launching with three flower strains, all of which will be available at The Apothecarium, including: Diablo Wind (sativa), Pancake Ice (sativa) and Pink Moon (indica). Like their founder’s groundbreaking film “Pineapple Express”, Houseplant strains are named after weather phenomena. Each strain will be sold in a custom tin.
“We are so proud to be one of the very first dispensaries in California to offer Houseplant to our customers,” said Ryan Hudson , CEO and co-founder of The Apothecarium. “Seth, Evan and everyone at Houseplant love and respect cannabis as much as we do. We simply cannot wait to share their beautiful and delicious flowers with our guests.”
“We’ve been working with the Houseplant team for more than a year and are grateful to have a partner that shares so many of our values, including an emphasis on cannabis education, quality, reform of cannabis laws and beautifully designed, recyclable packaging.”
“Seth has been hands-on during the process, spending time with our store managers to make sure they know the products and how much care has gone into vetting and selecting the best strains. We think our guests are going to love Houseplant.”
About The Apothecarium
The Apothecarium is recognized as one of the nation’s premier cannabis dispensaries, with an emphasis on education via in-depth one-on-one consultations from highly trained cannabis consultants. The company was founded by three first cousins and two family friends in 2011. Our dispensaries are known for providing educational events that are open to the public at no cost — and for welcoming seniors, first-time dispensary visitors, and people with serious medical conditions. The Apothecarium’s flagship San Francisco dispensary was named the best-designed dispensary in the country by Architectural Digest . Patients and customers may order at our dispensaries or online for pickup or delivery at apothecarium.com [apothecarium.com] .
The Apothecarium is committed to giving back to the communities we serve. We have donated more than $400,000 in cash to community groups and nonprofits — plus more than $300,000 worth of in-kind donations.
All Apothecarium dispensaries continue to implement safety measures to protect guests and team members. Protocols include strict social distancing inside and outside the dispensaries, a mask requirement for everyone inside the dispensaries, no contact check-in procedures and ongoing sanitizing throughout the day.
CA Licenses: C10-0000523-LIC; C10-0000522-LIC; C10-0000515-LIC, C10-0000738-LIC, C10-0000706-LIC
News Provided by Canada Newswire via QuoteMedia
MISSISSAUGA, Ontario TheNewswire – April 16, 2021 Sire Bioscience Inc. (CSE:SIRE) (OTC:BLLXF) (FSE:BR1B) (CNSX:SIRE.CN) (“SIRE” or the “Company”) announces that Brian Nugent has resigned as a member of the Company’s board of directors (the “ Board ”). It has been a pleasure and a blessing to have worked with Brian Nugent over the past few years, his business acumen and tremendous experience will certainly be missed, SIRE wishes him nothing but the best in all his future endeavors.
About Sire Bioscience
SIRE is headquartered in Mississauga, Ontario with its wholly owned subsidiary PLANTFUEL® based in Denver, Colorado. SIRE is managed by a group of successful entrepreneurs who have extensive experience in the areas of consumer-packaged goods, manufacturing, logistics, and distribution. SIRE is a CPG life science company focused on the plant-based foods and supplements industry.
For additional information contact:
Sire Bioscience Inc.
Copyright (c) 2021 TheNewswire – All rights reserved.
News Provided by TheNewsWire via QuoteMedia